The next step in the clinical evaluation of LRRK2 inhibition for #Parkinsons begins: Denalitx and Biogen have initiated dosing in the Phase 2b LUMA study to evaluate the efficacy & safety of BIIB122 (DNL151 vs placebo) in 640 participants with early-stage PD
Denalitx and Biogen have initiated dosing... - Cure Parkinson's
Denalitx and Biogen have initiated dosing in the Phase 2b LUMA study to evaluate efficacy & safety of BIIB122 (DNL151 vs placebo)
Not what you're looking for?
You may also like...
Phase 3, the Lighthouse study, Biogen and Denali, LRRK2 inhibitor BIIB122; New clinical trial registered
registered: Biogen and Denaliti have initiated the 2nd late-stage study of their LRRK2 inhibitor...
AnnovisBio has initiated a 6-month Phase 3 study to evaluate 2 different doses Buntanetap (posiphen) in 450 participants with PD
AnnovisBio has initiated a 6-month, placebo-controlled, double-blind Phase 2 study to evaluate...
Phase 4 study to evaluate efficacy of orally administrated Trehalose in individuals with idiopathic & LRRK2-associated Parkinsons
idiopathic & LRRK2-associated #Parkinsons...
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
samples accounting for placebo.
https://www.globenewswire.com/news-release/2024/05/09/2878650/0/e
Gene therapy is underway!
https://parkinsonsnewstoday.com/2021/02/26/biogen-sangamo-partners-developing-novel-gene-therapies/
2021 Should be An Informative Year
Quite an interesting article. Thoughts?
Phase 3 Positive Topline Results for Tavapadon 
Annovis Bio Buntanetap Interim Analysis of the Parkinson's Clinical Study
